Neuroscientific Biopharmaceuticals Ltd. (AU:NSB) has released an update.
NeuroScientific Biopharmaceuticals Ltd has reached a pivotal milestone following constructive feedback from the FDA on their pre-IND meeting for EmtinB, an innovative treatment for advanced glaucoma. The company also announced the appointment of Dr. Tony Keating as an Executive Director and reported a solid cash position of A$4.954M, while continuing to explore new opportunities to enhance their portfolio. Their financial management has allowed for a consistent cash burn rate, expected to continue into the next quarter.
For further insights into AU:NSB stock, check out TipRanks’ Stock Analysis page.
